Zinner elected chair of American College of Surgeons board of regents

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MICHAEL ZINNER was elected chair of the Board of Regents of the American College of Surgeons.

Zinner is a general surgeon with expertise in pancreatic-hepatobiliary diseases. Since 2016, he has been the founding chief executive officer and executive medical director of the Miami Cancer Institute–Baptist Health South Florida.

Prior to that time, he served as surgeon-in-chief and Moseley Professor of Surgery at the Brigham and Women’s Hospital and Harvard Medical School. During this time, Zinner also served as clinical director and chief of surgical services at the Dana-Farber/Brigham and Women’s Cancer Center.

A fellow of the American College of Surgeons (FACS) since 1983, Zinner has previously served as vice-chair of the ACS Board of Regents (2010-2015) and chair of the ACS Board of Governors (2008-2010).

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login